Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market in Focus: Forecasting Growth Drivers, Scaling Potential, and Global Opportunities
Discover trends, market shifts, and competitive outlooks for the sodium glucose cotransporter 2 (sglt2) inhibitors industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What is the Anticipated CAGR of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, and What Factors Will Drive It?
The market size of the sodium glucose cotransporter 2 (SGLT2) inhibitors has seen a robust growth in the past few years. The market, which is at $10.17 billion in 2024, is expected to escalate to $11.07 billion in 2025, marking a compound annual growth rate (CAGR) of 8.8%. Positive outcomes from early clinical trials, increasing regulatory authorizations, a surge in the diagnosis rate of diabetes, and the need for innovative diabetes treatments are the key factors that have contributed to the growth during the previous period.
The market for sodium glucose cotransporter 2 (SGLT2) inhibitors is predicted to experience substantial growth in the upcoming years, expanding to $15.4 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. This expectant growth during the forecast period is primarily driven by an increase in diabetes cases, a rise in obesity levels, heightened awareness around diabetes management, and broadening uses in the treatment of heart and kidney diseases. Key trends during this period encompass the incorporation of combination therapies, the adoption of personalized medical practices, advancements in technology, and classic drug development approaches.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
Which Factors and External Forces Are Driving Demand in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
The sodium glucose cotransporter 2 (SGLT2) inhibitor market is predicted to expand due to the growing incidence of diabetes. Diabetes is a cluster of metabolic diseases marked by elevated blood sugar caused by issues in insulin production, insulin function, or both. The surge in diabetes cases has been linked to elements like urbanization, stress, environmental pollutants and inadequate healthcare access. SGLT2 inhibitors, which are utilized to control diabetes, work by reducing blood glucose levels, inhibiting glucose reuptake in the kidneys resulting in glucose elimination through urine. These inhibitors also provide cardiovascular and kidney advantages, rendering them an important resource for managing diabetes and its related complications. As an example, data from the Australian Bureau of Statistics in December 2023 revealed that 5.3% of Australians, approximately 1.3 million individuals, were identified with diabetes in 2022, with similar levels in males (5.8%) and females (4.9%). The frequency of diabetes has been growing steadily, notably increasing with age, peaking at 18.7% in people aged 75 and up. Type 2 diabetes is the most prevalent, comprising 87.6% of all cases. Factors such as being born overseas, residing in underprivileged areas, and having a disability correlate with higher diabetes rates. As such, the rising incidence of diabetes is fueling the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.
How Is the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Segmented?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp
What Are the Fastest-Growing Geographies in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry Dynamics?
Leading firms in the SGLT2 inhibitor market are concentrating their efforts on creating dual inhibitor therapeutic strategies to enhance patient results and control blood sugar levels. Dual inhibitor therapeutic strategies are treatments that concurrently target two distinct sodium-glucose cotransporters (SGLT1 and SGLT2) to increase the effectiveness in handling conditions like heart failure and diabetes. For example, Lexicon Pharmaceuticals Inc., a biopharmaceutical company from the US, received approval from the Food and Drug Administration (FDA) in May 2023 for a heart failure treatment called sotagliflozin. This innovative dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily pill meant to reduce death from cardiovascular issues, hospitalizations due to heart failure, and urgent visits because of heart failure in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risks. The benefits of this treatment include decreased renal glucose and sodium reabsorption, which contribute to reducing preload and afterload and lowering sympathetic activity.
View the full report here:
How Is the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Defined and What Are Its Core Parameters?
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This helps lower blood glucose levels and can also contribute to weight loss and reduced blood pressure. They have additional cardiovascular and renal benefits, making them valuable in managing diabetic complications.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
